Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

Research scientists working in laboratory

Bisphosphonates, a drug class used to prevent the loss of bone density, are the first-line treatment for preventing fracture in osteoporosis patients. Osteoporosis is often associated with patients with chronic kidney disease (CKD), who can suffer from low bone density and increased fracture risk, but there was little information available on the safety of bisphosphonates in patients with CKD.

Moderate to severe (stages 3-5) chronic kidney disease (CKD) affects up to 2.8 million people in the UK and 2.7 million people in Spain.

The Prieto-Alhambra Group for pharmaco- and device epidemiology at NDORMS, in collaboration with SIDIAP, set out to understand the safety profile of bisphosphonates in patients with moderate to severe CKD. Using primary-care electronic records from two patient cohorts in the UK and Catalonia, Spain, they analysed the data from 4,000 bisphosphonate users and more than 15,000 non-users.

Victoria Strauss, lead statistician at NDORMS said: “Our primary outcome was CKD stage worsening, the risk that patients may move to a more severe form of the disease and which could potentially lead to dialysis or transplant. We saw a modest (15%) risk of CKD progression with bisphosphonate use. This adds to the body of work in this area and should act as a guide to clinicians to carefully consider the risk-benefit of prescribing bisphosphonate to moderate to severe CKD patients for the management of osteoporosis.”

The study found no risk differences for acute kidney injury, gastrointestinal bleeding/ulcers, or hypocalcaemia.

The study, published in JMBR (Journal of Molecular Biology Research), was funded by the Health Technology Assessment Programme, and the Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable, and supported by the NIHR Bio-medical Research Centre.

Similar stories

New children’s orthopaedic hospital opens in Zimbabwe

Main

A new children’s orthopaedic hospital in Bulawayo that will treat children across Zimbabwe who are living with musculoskeletal impairments has opened today.

Professor Katja Simon elected to the Academy of Medical Sciences

Awards Kennedy Main

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.